Get the Stockscreener App
13.52
0.22%
0.03
After Hours:
13.53
0.010
+0.07%
Organon Co stock is traded at $13.52, with a volume of 3.02M.
It is up +0.22% in the last 24 hours and up +1.05% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$13.49
Open:
$13.49
24h Volume:
3.02M
Relative Volume:
0.37
Market Cap:
$3.55B
Revenue:
$6.16B
Net Income/Loss:
$246.00M
P/E Ratio:
14.40
EPS:
0.9387
Net Cash Flow:
$708.00M
1W Performance:
-0.22%
1M Performance:
+1.05%
6M Performance:
+67.95%
1Y Performance:
+34.93%
1-Day Range:
$13.48
$13.53
1-Week Range:
$13.46
$13.58
52-Week Range:
$5.69
$13.60
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.52 | 3.55B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Sun Pharma to Acquire Organon in US$11.75 Billion Deal, Strengthening Global Healthcare Portfolio - eHealth Magazine
Organon (OGN) Q1 2026 earnings summary - Quartr
Price-Driven Insight from (OGN) for Rule-Based Strategy - Stock Traders Daily
Organon (OGN) Proxy filing Summary - Quartr
SBI Joins 10 Global Lenders in Sun Pharma's Organon Financing Deal - outlookbusiness.com
SBI joins global banks to fund Sun's Organon buy - Magzter
What Sparked Organon's Recent Stock Surge - Kavout | AI
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada - AOL.com
SBI joins global banks to fund Sun Pharma's $11.75 billion Organon buy - Business Standard
Organon to present VTAMA cream data at pediatric dermatology meeting - Investing.com
Organon to present VTAMA cream data at pediatric dermatology meeting By Investing.com - Investing.com Nigeria
Organon’s VTAMA data heads to pediatric dermatology meeting - Stock Titan
Sun Pharma's $11.8 bn Organon buy drives India's M&A value to 4-year high - Business Standard
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
OGNOrganon & Co Volatility & Greeks - Finviz
OGN Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesShare Repurchase Impact - dars.gov.et
Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets? - Insider Monkey
Organon & Co. Actuals & Estimates (NYSE:OGN) - TradingView
Organon & Co updates strategic focus, shares watched on NYSE - AD HOC NEWS
Organon wins FDA nod to expand TOFIDENCE use in severe CRS & COVID-19 - MSN
Class Action Lawsuit Filed: Organon & Co. (OGN)Join by July 22, 2025Contact Levi & Korsinsky - The National Law Review
Enterprise value to EBITDA forward of Organon & Co. – MUN:7XP - TradingView
Price to earnings forward of Organon & Co. – NYSE:OGN - TradingView
Price to earnings forward of Organon & Co. – LSE:0A9W - TradingView
Organon and Henlius launch Prolia and Xgeva biosimilars in Canada - MSN
Mayne Pharma appoints former Organon & Co executive Meghan Rivera to board - MSN
(OGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Price to sales forward of Organon & Co. – NYSE:OGN - TradingView
Enterprise value to EBITDA forward of Organon & Co. – LSE:0A9W - TradingView
Enterprise value to revenue forward of Organon & Co. – NYSE:OGN - TradingView
Shareholders of Organon & Co. (OGN): Protect Your Rights Before July 22, 2025Contact Levi & Korsinsky - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Stockholders to Connect - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Organon & Co. (OGN) InvestorsLead Plaintiff Deadline on July 22, 2025 - The National Law Review
OGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
FINAL OGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Org - The National Law Review
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Organon & Co. (OGN) - The National Law Review
Lost Money on Organon & Co. (OGN)? Urged to Join Class Action Before July 22, 2025Contact Levi & Korsinsky - The National Law Review
Securities Fraud Class Action Filed Against Organon & Co. (OGN) - The National Law Review
Enterprise value to EBIT forward of Organon & Co. – LSE:0A9W - TradingView
Organon & Co updates earnings timing, shares watched by health care investors - Ad-hoc-news.de
Organon celebrates 5 years of expanding healthcare access - Manila Standard
Organon & Co (OGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organon & Co stock hits 52-week high at $13.49 - Investing.com UK
Organon & Co stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? - TradingView
OGN Forecast — Price Target — Prediction for 2027 - TradingView
Gorvins supports Organon Trustees through acquisition process - Marketing Stockport
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):